

**Experiment Number:** C11042

**Test Type:** TOX

**Route:** Oral Gavage

**Species/Strain:** Rat/Harlan Sprague Dawley

**C Number:**

C11042

**Cage Range:**

All

**Date Range:**

All

**Reasons For Removal:**

All

**Removal Date Range:**

All

**Treatment Groups:**

All

**Study Gender:**

Male

**PA41: Clinical Chemistry Summary**

**Test Compound:** Triphenyl Phosphate

**CAS Number:** 115-86-6

**Date Report Requested:** 03/28/2017

**Time Report Requested:** 11:00:37

**Lab:** NTP

Experiment Number: C11042

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary

Test Compound: Triphenyl Phosphate

CAS Number: 115-86-6

Date Report Requested: 03/28/2017

Time Report Requested: 11:00:37

Lab: NTP

Male

	Phase Day	Treatment Groups				
		0 mMol/kg	0.169 mMol/kg	0.338 mMol/kg	0.675 mMol/kg	1.35 mMol/kg
Urea Nitrogen (mg/dL)	SD 4	12.0 ± 0.8 (5)	11.6 ± 0.7 (5)	12.8 ± 1.3 (5)	13.8 ± 0.7 (5)	13.2 ± 1.2 (5)
Percent of Control			97	107	115	110
Creatinine (mg/dL)	SD 4	0.29 ± 0.01 (5)	0.28 ± 0.01 (5)	0.29 ± 0.02 (5)	0.26 ± 0.01 (5)	0.29 ± 0.01 (5)
Percent of Control			96	101	91	101
Total Protein (g/dL)	SD 4	5.94 ± 0.13 (5)	5.92 ± 0.14 (5)	5.90 ± 0.07 (5)	6.06 ± 0.08 (5)	6.12 ± 0.10 (5)
Percent of Control			100	99	102	103
Globulin (g/dL)	SD 4	2.50 ± 0.07 (5) **	2.56 ± 0.07 (5)	2.52 ± 0.05 (5)	2.66 ± 0.05 (5)	2.76 ± 0.06 (5)
Percent of Control			102	101	106	110
A/G Ratio	SD 4	1.38 ± 0.03 (5) **	1.31 ± 0.01 (5)	1.34 ± 0.02 (5)	1.28 ± 0.02 (5) *	1.22 ± 0.03 (5) **
Percent of Control			95	97	93	88
Albumin (g/dL)	SD 4	3.44 ± 0.07 (5) *	3.36 ± 0.07 (5)	3.38 ± 0.04 (5)	3.40 ± 0.04 (5)	3.36 ± 0.06 (5)
Percent of Control			98	98	99	98
Cholesterol (mg/dL)	SD 4	101.0 ± 5.8 (5) **	115.0 ± 6.5 (5)	122.4 ± 6.2 (5)	127.8 ± 6.3 (5) *	145.4 ± 7.3 (5) **
Percent of Control			114	121	127	144
Triglyceride (mg/dL)	SD 4	54.0 ± 6.0 (5) *	53.8 ± 1.4 (5)	61.6 ± 6.8 (5)	74.0 ± 6.1 (5)	53.0 ± 5.3 (5)
Percent of Control			100	114	137	98
LDL Cholesterol (mg/dL)	SD 4	21.8 ± 0.7 (5) **	21.8 ± 1.1 (5)	23.2 ± 0.9 (5)	23.8 ± 1.5 (5)	23.4 ± 1.1 (5)
Percent of Control			100	106	109	107
HDL Cholesterol (mg/dL)	SD 4	46.0 ± 2.9 (5) **	54.6 ± 2.7 (5)	56.8 ± 2.8 (5) *	60.6 ± 2.9 (5) **	70.6 ± 3.2 (5) **
Percent of Control			119	123	132	153
Alanine Aminotransferase (IU/L)	SD 4	61.40 ± 4.46 (5)	77.40 ± 6.55 (5)	63.80 ± 5.54 (5)	65.00 ± 5.37 (5)	65.60 ± 6.25 (5)
Percent of Control			126	104	106	107

Experiment Number: C11042

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary

Test Compound: Triphenyl Phosphate

CAS Number: 115-86-6

Date Report Requested: 03/28/2017

Time Report Requested: 11:00:37

Lab: NTP

---

Male

---

		Treatment Groups				
	Phase Day	0 mMol/kg	0.169 mMol/kg	0.338 mMol/kg	0.675 mMol/kg	1.35 mMol/kg
Aspartate Aminotransferase (U/L) Percent of Control	SD 4	107.40 ± 10.21 (5)	94.60 ± 10.38 (5) 88	97.80 ± 9.82 (5) 91	73.00 ± 2.17 (5) * 68	80.80 ± 9.89 (5) 75
Sorbitol Dehydrogenase (IU/L) Percent of Control	SD 4	10.4 ± 0.7 (5)	11.8 ± 1.1 (5) 113	12.7 ± 1.6 (5) 122	10.4 ± 0.7 (5) 100	10.8 ± 0.7 (5) 103
Bile salt/acids (umol/L) Percent of Control	SD 4	57.4 ± 8.8 (5)	39.5 ± 5.5 (5) 69	26.6 ± 3.2 (5) * 46	37.2 ± 6.3 (5) 65	36.2 ± 10.2 (5) 63

**Experiment Number:** C11042

**Test Type:** TOX

**Route:** Oral Gavage

**Species/Strain:** Rat/Harlan Sprague Dawley

**PA41: Clinical Chemistry Summary**

**Test Compound:** Triphenyl Phosphate

**CAS Number:** 115-86-6

**Date Report Requested:** 03/28/2017

**Time Report Requested:** 11:00:37

**Lab:** NTP

---

**Male**

---

**Treatment Groups**

	<b>Phase Day</b>	<b>2.70 mMol/kg</b>
Urea Nitrogen (mg/dL)	SD 4	30.6 ± 17.2 (5)
Percent of Control		255
Creatinine (mg/dL)	SD 4	0.40 ± 0.11 (5)
Percent of Control		139
Total Protein (g/dL)	SD 4	5.84 ± 0.15 (5)
Percent of Control		98
Globulin (g/dL)	SD 4	2.72 ± 0.15 (5)
Percent of Control		109
A/G Ratio	SD 4	1.16 ± 0.07 (5) **
Percent of Control		84
Albumin (g/dL)	SD 4	3.12 ± 0.06 (5) *
Percent of Control		91
Cholesterol (mg/dL)	SD 4	170.0 ± 19.4 (5) **
Percent of Control		168
Triglyceride (mg/dL)	SD 4	140.6 ± 59.1 (5)
Percent of Control		260
LDL Cholesterol (mg/dL)	SD 4	32.8 ± 6.4 (5) *
Percent of Control		150
HDL Cholesterol (mg/dL)	SD 4	78.2 ± 5.1 (5) **
Percent of Control		170
Alanine Aminotransferase (IU/L)	SD 4	116.60 ± 32.10 (5)
Percent of Control		190

**Experiment Number:** C11042

**Test Type:** TOX

**Route:** Oral Gavage

**Species/Strain:** Rat/Harlan Sprague Dawley

**PA41: Clinical Chemistry Summary**

**Test Compound:** Triphenyl Phosphate

**CAS Number:** 115-86-6

**Date Report Requested:** 03/28/2017

**Time Report Requested:** 11:00:37

**Lab:** NTP

---

**Male**

---

**Treatment Groups**

	<b>Phase Day</b>	<b>2.70 mMol/kg</b>
Aspartate Aminotransferase (U/L)	SD 4	150.80 ± 46.99 (5)
Percent of Control		140
Sorbitol Dehydrogenase (IU/L)	SD 4	11.9 ± 1.0 (5)
Percent of Control		114
Bile salt/acids (umol/L)	SD 4	38.9 ± 5.5 (5)
Percent of Control		68

**Experiment Number:** C11042

**Test Type:** TOX

**Route:** Oral Gavage

**Species/Strain:** Rat/Harlan Sprague Dawley

**PA41: Clinical Chemistry Summary**

**Test Compound:** Triphenyl Phosphate

**CAS Number:** 115-86-6

**Date Report Requested:** 03/28/2017

**Time Report Requested:** 11:00:37

**Lab:** NTP

#### LEGEND

---

SD – Study Day; GD – Gestation Day; LD – Lactation Day; PND – Postnatal Day, adults post-weaning

Values given as mean  $\pm$  SEM (N) with Percent of Control calculated by (dosed group mean / control group mean) x 100

Clinical Chemistry for gestation phase includes pregnant females only

Statistical analysis performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

\* Statistically significant at  $P \leq 0.05$

\*\* Statistically significant at  $P \leq 0.01$

**\*\* END OF REPORT \*\***